Marisa Fernandes das Neves1, Rajendra Vara Prasad Irlapati2, David Isenberg3. 1. Medicine IV Department, Fernando Fonseca Hospital, Amadora, CEDOC - Chronic Diseases, Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal. 2. Department of Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, India and. 3. Centre for Rheumatology, Department of Medicine, University College London, London, UK d.isenberg@ucl.ac.uk.
Abstract
OBJECTIVE: To review the likelihood of very long-term remission in patients with biopsy-proven LN attempting to identify good prognostic features. METHODS: We reviewed patients with LN whose renal biopsies showed World Health Organization (WHO) classes III, IV and V and who had a follow-up of at least 5 years between 1973 and 2008. We analysed demographic, clinical, laboratory and therapeutic parameters comparing those patients with (group A) and without (group B) 5 year remission. RESULTS: Of 191 LN patients followed, 105 patients met the strict inclusion criteria. Ninety-five patients were female. Mean age at diagnosis of lupus was 24.1 years (s.d. 10.7). ean age at diagnosis of LN was 28.4 years (s.d. 11.3). The mean duration of follow-up was 13.7 years (s.d. 14.1). Forty (38%) patients achieved 5 year remission, of whom 17 (16.2%) had remission for ≥15 years. The incidence of flares per year from 5 to 15 years was 7.9%; however, no flares were observed after 15 years of remission. The only distinguishing feature found in this study was the association of WHO class IV on kidney biopsy with LN progression (P = 0.03). CONCLUSION: Renal histology with WHO class IV predicted a poor long-term remission rate. Age, sex, ethnicity, serological parameters and treatment received did not predict long-term remission. Renal flares can occur up to 15 years after a patient has gone into remission.
OBJECTIVE: To review the likelihood of very long-term remission in patients with biopsy-proven LN attempting to identify good prognostic features. METHODS: We reviewed patients with LN whose renal biopsies showed World Health Organization (WHO) classes III, IV and V and who had a follow-up of at least 5 years between 1973 and 2008. We analysed demographic, clinical, laboratory and therapeutic parameters comparing those patients with (group A) and without (group B) 5 year remission. RESULTS: Of 191 LN patients followed, 105 patients met the strict inclusion criteria. Ninety-five patients were female. Mean age at diagnosis of lupus was 24.1 years (s.d. 10.7). ean age at diagnosis of LN was 28.4 years (s.d. 11.3). The mean duration of follow-up was 13.7 years (s.d. 14.1). Forty (38%) patients achieved 5 year remission, of whom 17 (16.2%) had remission for ≥15 years. The incidence of flares per year from 5 to 15 years was 7.9%; however, no flares were observed after 15 years of remission. The only distinguishing feature found in this study was the association of WHO class IV on kidney biopsy with LN progression (P = 0.03). CONCLUSION: Renal histology with WHO class IV predicted a poor long-term remission rate. Age, sex, ethnicity, serological parameters and treatment received did not predict long-term remission. Renal flares can occur up to 15 years after a patient has gone into remission.
Authors: David J Tunnicliffe; Suetonia C Palmer; Lorna Henderson; Philip Masson; Jonathan C Craig; Allison Tong; Davinder Singh-Grewal; Robert S Flanc; Matthew A Roberts; Angela C Webster; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2018-06-29
Authors: Carolina Landolt-Marticorena; Stephenie D Prokopec; Stacey Morrison; Babak Noamani; Dennisse Bonilla; Heather Reich; James Scholey; Carmen Avila-Casado; Paul R Fortin; Paul C Boutros; Joan Wither Journal: Arthritis Res Ther Date: 2016-10-04 Impact factor: 5.156
Authors: Eleni Kapsia; Smaragdi Marinaki; Ioannis Michelakis; George Liapis; Petros P Sfikakis; John Boletis; Maria G Tektonidou Journal: J Clin Med Date: 2022-08-26 Impact factor: 4.964
Authors: Filipa Farinha; Ruth J Pepper; Daniel G Oliveira; Thomas McDonnell; David A Isenberg; Anisur Rahman Journal: Rheumatology (Oxford) Date: 2020-11-01 Impact factor: 7.046
Authors: Myrto Kostopoulou; Antonis Fanouriakis; Kim Cheema; John Boletis; George Bertsias; David Jayne; Dimitrios T Boumpas Journal: RMD Open Date: 2020-07